00719.HK
Shandong Xinhua Pharmaceutical Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 5.65
+0.53%Year over year
Reported trailing growth
- Revenue
- +0.7%
- EBITDA
- -18.6%
- EBIT
- -43.8%
- EPS
- -48.3%
- Free cash flow
- +148.7%
- Operating cash flow
- +99.1%
Forward estimates
Based on analyst estimates
- Revenue
- -8.5%
- EBITDA
- +225.9%
- EPS
- +228.2%
Three-year CAGR
- Revenue
- +5.3%
- EBITDA
- -0.7%
- EBIT
- -8.6%
- Net income
- -11.0%
- EPS
- -12.2%
- Free cash flow
- -6.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026